Gene Therapy on Cardiovascular Disease Market Size, Share & Trends Analysis Report By Type (Viral Gene Therapy, Non-Viral Gene Therapy), By Application (Heart Disease, Vascular Disease), By Region, And By Segment Forecasts, 2024-2031.

Gene Therapy on Cardiovascular Disease Market Size is predicted to grow at a 67.4% CAGR during the forecast period for 2024-2031.

Gene therapy for cardiovascular disease shows promising potential but is primarily in the experimental and clinical trial stages. Achievement in this domain has the potential to result in groundbreaking therapies for conditions that presently possess restricted therapeutic alternatives. One approach to gene therapy that makes use of viral vectors is the delivery of therapeutic genes to cells in the cardiovascular system. Gene therapy for cardiovascular illness is seeing increased demand for a variety of reasons. As a primary cause of mortality globally, cardiovascular disease has an urgent need for improved treatment options.

Further, advancements in gene delivery technology and genetic engineering have made it feasible to create and deliver therapeutic genes more safely and efficiently. The rising incidence of long-term diseases, including cancer, rare genetic disorders affecting a wide range of uncommon diseases, and others, is a major force propelling the gene therapy market forward. Several factors, including rising cancer rates, ethical acceptance of gene therapy as a cancer treatment, and more government support, drive market expansion.

However, the market growth is hampered by the high-cost criteria for the safety and health of gene therapy in the cardiovascular disease market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high low code technology in insurance, because of the lack of payment criteria and adequate insurance coverage, the therapeutic procedures have become prohibitively expensive. Coverage of gene therapies, especially for uncommon diseases or syndromes, may be hesitant by insurance companies and healthcare providers because of the lack of data on the long-term safety and effectiveness of these treatments. The total expansion of the gene therapy market for cardiovascular illness may be hindered, and patients may find it difficult to receive these medicines. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories in an effort to protect their personnel from contracting the virus, the expansion of the industry may be hindered.

Competitive Landscape

Some Major Key Players In The Gene Therapy on Cardiovascular Disease Market:

• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• Sunway Biotech
• bluebird bio
• SIBIONO
• AnGes
• Orchard Therapeutics
• Other Market Players

Market Segmentation:

Gene therapy in the cardiovascular disease market is segmented based on type and application. As per the type, the market is segmented into viral gene therapy and non-viral gene therapy. By application, the market is segmented into heart disease and vascular disease.

Based On The Type, The Viral Gene Therapy Segment Is Accounted As A Major Contributor To The Gene Therapy On Cardiovascular Disease Market 

Viral gene therapy in the cardiovascular disease market is expected to lead with a major global market share in 2023. The use of viral vectors to treat hereditary diseases like muscular dystrophy and cystic fibrosis is very promising. They pave the door for better patient outcomes by delivering functional genes that attenuate genetic mutations.

Vascular Disease Segment To Witness Growth At A Rapid Rate.

Vascular disease makes up the bulk of acrylic acid ester usage because it impacts the blood vessels or circulatory system. From circulatory illnesses to those affecting the arteries, veins, and lymph vessels, this covers almost everything, especially in countries like the US, Germany, the U.K., China, and India.

In The Region, The North American Gene Therapy On Cardiovascular Disease Market Holds A Significant Revenue Share.

The North American gene therapy in the cardiovascular disease market is expected to record a large market revenue share in the near future. It can be attributed to the prevalence of chronic diseases, high and rising healthcare expenditure, an advanced healthcare infrastructure, available reimbursements, and the presence of major market players. In addition, Europe is predicted to grow rapidly in the global gene therapy in cardiovascular disease market due to the huge amount of registered clinical trials linked to the treatments. The significant focus on government funding and reforms is another factor expected to contribute to expanding the region's chimeric antigen gene therapy market in the coming years.

Recent Developments:

• In Nov 2023, Amgen presented new information at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, which further supports the safety and effectiveness of Repatha® (evolocumab) based on the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial. The presentations will specifically address the reduction of LDL "bad" cholesterol (LDL-C), which is a well-known risk factor for cardiovascular disease (CVD). 

• In Aug 2023, Lexeo Therapeutics received a strategic investment from Sarepta Therapeutics to aid in the advancement of Lexeo's cardiovascular gene therapies. The companies will investigate the creation of innovative gene therapy candidates for various cardiovascular diseases as part of this investment.

Gene Therapy on Cardiovascular Disease Market Report Scope: